Burn News and Research

RSS

FDA grants 510(k) clearance for Derma Sciences MEDIHONEY Gel Wound and Burn Dressing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company's patent-pending MEDIHONEY® Gel Wound and Burn Dressing.

28 Feb 2011

BioCryst receives HHS contract to complete peramivir Phase 3 study in patients with influenza

BioCryst Pharmaceuticals, Inc. announced that it has been awarded a $55.0 million contract modification by the U.S. Department of Health & Human Services intended to fund to completion the Phase 3 development of its neuraminidase inhibitor, intravenous peramivir, for the treatment of patients hospitalized with influenza.

25 Feb 2011

FDA approves sBLA for CSL's Hizentra to treat PI

CSL Behring announced today that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application to extend the shelf life of Hizentra, Immune Globulin Subcutaneous, 20% Liquid, from 24 months to 30 months.

24 Feb 2011

FDA refuses Delcath's chemosaturation delivery system NDA filing

Delcath Systems, Inc. announced today that the Company has received a "refusal to file" letter from the U.S. Food & Drug Administration for the New Drug Application for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride.

22 Feb 2011

Research: Blood and hormone level in saliva can reveal burnout symptoms

Your blood and the level of a hormone in your spit could reveal if you're on the point of burnout, according to research undertaken by Dr. Sonia Lupien and Robert-Paul Juster of the Centre for Studies on Human Stress of Louis-H. Lafontaine Hospital and the University of Montreal.

22 Feb 2011

HealthPort announces participation in test phase of CMS esMD gateway services

HealthPort, an industry authority in the HIPAA-compliant transfer of protected health information and audit management technology, today announced its involvement as the largest health information handler approved to participate in the test phase of the Centers for Medicare & Medicaid Services' electronic submission of medical documentation gateway services for information exchange from healthcare providers.

21 Feb 2011

International study shows reprogramming cells lead to genomic aberrations

It's a discordant note in the symphony of good news that usually accompanies stem cell research announcements. Stem cells hold enormous promise in regenerative medicine, thanks to their ability to regenerate diseased or damaged tissues.

21 Feb 2011

FDA grants CSL Behring marketing approval for Corifact in treatment of congenital FXIII deficiency

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.

19 Feb 2011

Viewpoints: Arizona's waiver; next gen's 'different' Medicare?; individual mandate's constitutionality

There may be no federal obstacles to cutting 250,000 people out of AHCCCS, part of Gov. Jan Brewer's budget proposal. But there are compelling reasons to avoid such a drastic step if at all possible. And it's possible.

17 Feb 2011

Inspire announces strategic corporate restructuring on its eye care business

Inspire Pharmaceuticals, announced today a strategic corporate restructuring designed to result in the Company focusing activities on its eye care business, allowing it to fully leverage existing commercial capabilities, pipeline assets and related corporate development and licensing opportunities.

17 Feb 2011

Inspire fourth quarter revenues increase 2% to $30.3 million

Inspire Pharmaceuticals, announced today financial results for the fourth quarter and year ended December 31, 2010. For the quarter ended December 31, 2010, the Company reported a net loss of $4.3 million, or per common share, compared to a net loss of $2.6 million, or per common share, for the same period in 2009.

17 Feb 2011

Passion for dancing helps beat breast cancer

When Karen Franklin was diagnosed with breast cancer last year, it was her passion for Zumba® that helped her beat the disease. Franklin's story, say experts at The University of Texas MD Anderson Cancer Center, reminds us about exercise's cancer-fighting benefits.

16 Feb 2011

New algorithm guides plastic surgeons in managing women with ALCL after breast augmentation

In the wake of a recent FDA statement linking breast implants to a rare cancer called anaplastic large cell lymphoma, a newly updated algorithm provides plastic surgeons with guidance in managing women with breast lumps or swelling after breast augmentation.

15 Feb 2011

Microbix first quarter revenues decrease 34% to $812,694

Microbix Biosystems Inc., a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and livestock semen sexing, in addition to a core business of virology products, today reported financial results for the first quarter of fiscal 2011. For the quarter ended December 31, 2010, Microbix reported revenues of $812,694, a 34% decrease from $1,226,538 for the same period in 2009.

14 Feb 2011

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2010.

10 Feb 2011

Vical 2010 net loss increases to $30.4 million

Vical Incorporated today reported financial results for the year ended December 31, 2010. Vical had cash and investments of approximately $61 million at year-end 2010. The company received approximately $37 million of net proceeds from the sale of equity securities during 2010.

10 Feb 2011

DMC Children's Hospital of Michigan receives ABA and ACS Burn Center Verification

Last year at the DMC Children's Hospital of Michigan, nearly 500 children were treated and admitted for burn injuries. As a result of the spectrum of quality care provided to burn patients from the pre-hospital phase through the rehabilitation process and having met rigorous standards for specific criteria set by the American Burn Association and the Committee on Trauma of the American Colleges of Surgeons, the DMC Children's Hospital of Michigan burn center is now the state's only verified pediatric burn center exclusively dedicated to the needs of children.

10 Feb 2011

Clinical Data reports $2.0 million revenue for third quarter 2011

Clinical Data, Inc. today announced operational and financial results for the third fiscal quarter ended December 31, 2010. The Company received approval from the U.S. Food and Drug Administration (FDA) of Viibryd™ for the treatment of adults with major depressive disorder (MDD) on January 21, 2011.

9 Feb 2011

ACE: Hula hooping workouts offer substantial and positive results

The American Council on Exercise, America's leading authority on fitness and the largest nonprofit fitness certification, education and training organization in the world, today announced exclusive study findings that conclude hula hooping workouts offer substantial and positive results.

9 Feb 2011

Researchers report promising new approach to treat diabetic wounds, bed sores

Loyola University Health System researchers are reporting on a promising new approach to treating diabetic wounds, bed sores, chronic ulcers and other slow-to-heal wounds.

8 Feb 2011

Burn News and Research

FDA grants 510(k) clearance for Derma Sciences MEDIHONEY Gel Wound and Burn Dressing

BioCryst receives HHS contract to complete peramivir Phase 3 study in patients with influenza

FDA approves sBLA for CSL's Hizentra to treat PI

FDA refuses Delcath's chemosaturation delivery system NDA filing

Research: Blood and hormone level in saliva can reveal burnout symptoms

HealthPort announces participation in test phase of CMS esMD gateway services

International study shows reprogramming cells lead to genomic aberrations

FDA grants CSL Behring marketing approval for Corifact in treatment of congenital FXIII deficiency

Viewpoints: Arizona's waiver; next gen's 'different' Medicare?; individual mandate's constitutionality

Inspire announces strategic corporate restructuring on its eye care business

Inspire fourth quarter revenues increase 2% to $30.3 million

Passion for dancing helps beat breast cancer

New algorithm guides plastic surgeons in managing women with ALCL after breast augmentation

Microbix first quarter revenues decrease 34% to $812,694

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

Vical 2010 net loss increases to $30.4 million

DMC Children's Hospital of Michigan receives ABA and ACS Burn Center Verification

Clinical Data reports $2.0 million revenue for third quarter 2011

ACE: Hula hooping workouts offer substantial and positive results

Researchers report promising new approach to treat diabetic wounds, bed sores

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News